Celgene Corp $95.02

up +0.32


29/8/2014 04:00 PM  |  NASDAQ : CELG  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get CELG Trend Analysis - it has underperformed the S&P 500 by 54%

Partner Headlines

  1. 4 Biotechs That Might Be Bought Soon

    IBD
  2. #PreMarket Primer: Thursday, August 28: Russia Implicated Further In Ukrainian ...

    Benzinga
  3. Celgene rose 2.4%

    IBD
  4. Stocks Rise As Biotechs Lead; Amazon To Buy Twitch

    IBD
  5. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD
  6. Fast Money Traders Share The Stocks To Buy In An Uptrend Market

    Benzinga
  7. Biogen, Celgene In Buy Range; LinkedIn Coming Back

    IBD
  8. Stocks Rise As Biotechs Lead; Amazon To Buy Twitch

    IBD
  9. Stocks Higher With Biotechs Leading The Way

    IBD
  10. Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs

    IBD
  11. Main Indexes Slip From Highs; Biotechs Show Strength

    IBD
  12. #PreMarket Primer: Monday, August 25: Tension In Ukraine Runs High On Independence ...

    Benzinga
  13. Majority Of IBD 50 Firms Strong On Sponsorship

    IBD
  14. #PreMarket Primer: Thursday, August 21: Tension Between Russia And The ...

    Benzinga
  15. Jazz, Celgene Lead Top 4 Drugmaker Profit Margins

    IBD
  16. #PreMarket Primer: Thursday, August 14: Investors Are Unfazed By Weak Retail ...

    Benzinga
  17. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga
  18. Why Investors Should Closely Watch Celgene

    Benzinga
  19. ClearBridge Value: Making It A Top Mutual Fund Again

    IBD
  20. Cancer 'Cocktail' Passes Test

    IBD
  21. Amgen Cancer Drug Kyprolis Succeeds In Trial

    IBD
  22. Pharmacyclics Q2 Earnings Get Mixed Reception

    IBD
  23. Biotechs Fall Despite Beats

    IBD
  24. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  25. Thursday Morning Earnings Reports

    Benzinga
  26. Celgene, Alexion Earnings Top Street, But Stocks Fall

    IBD
  27. Stocks Up And Down At Open; Under Armour, Facebook Surge

    IBD
  28. Biogen, Gilead Crush Earnings Estimates On Hot Drugs

    IBD
  29. S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade

    IBD
  30. Biogen Trounces Q2 Estimates As Tecfidera Outperforms

    IBD
  31. Alexion, 3 Other Top Biotechs Reporting Earnings

    IBD
  32. Stocks Climb In Solid Trade; Chipotle Gaps Up, Breaks Out

    IBD
  33. IBD 50 Ends Week Lower But Skyworks Soars

    IBD
  34. Biogen Shares Rebound As Street Has A Change Of Heart

    IBD
  35. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  36. IBD 50 Ends Week Lower But Skyworks Soars

    IBD
  37. Biotech Enters Reporting Season With Large Caps Central To Sector Performance

    Benzinga
  38. UPDATE: Morgan Stanley Reiterates On Celgene As EU Patents Risk May Be ...

    Benzinga
  39. Yellen Swats Down Biotech, Social Media Stocks

    FoxBusiness
  40. Stocks Close Higher As Biotech, Internet Stocks Gain

    IBD
  41. Celgene's Otezla fails trial

    IBD
  42. Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback

    Benzinga
  43. Celgene Drug Otezla Fails Trial, But Street Sanguine

    IBD
  44. Celgene Slips; Drug Candidate Fails Phase III Trial Endpoint

    Benzinga
  45. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  46. Spectrum lymphoma drug OK'd

    IBD
  47. Spectrum Pharma Lymphoma Drug Approved Early

    IBD
  48. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  49. Chipotle, Keurig Near Buy Points; Energy Dominates

    IBD
  50. Markets Little Changed As The Quarter Comes To An End

    Benzinga
Trading Center